

AMENDED CLAIMS

[received by the International Bureau on 17 November 2004 (17.11.2004);
original claims 1 and 5 amended; remaining claims unchanged (1 page)]

10/562 460

1. Use of a composition comprising acetogenic fibres for the preparation of a nutritional and/or a pharmaceutical composition for treating, preventing and/or improving insulin resistance.
2. The use according to claim 1, wherein the acetogenic fibre is lactulose, citrus pectin, apple pectin, carrot pectin, soybean fibre, soy fibre, acacia gum, gum Arabic or a mixture thereof.
3. The use according to claim 1 or 2, wherein the amount of acetogenic fibres in the composition is in the range of from 0.2 to 90 % by weight, preferably from 0.5 to 50 % by weight, more preferably 0.7 to 30 % by weight, even more preferably 5 to 25 % by weight, most preferred about 7 % by weight, based on the total weight of the composition.
4. The use according to any preceding claim, for increasing insulin sensitivity and/or preventing dyslipidemia.
5. A method for treating, preventing and/or improving insulin resistance which comprises administering an effective amount of a composition comprising acetogenic fibres.
6. The method of claim 5 wherein the acetogenic fibres are administered in an amount of from 0.1 to 1.5g per kg body weight, preferably from 0.3 to 0.8g per kg body weight, more preferably 0.5 g per kg body weight

Claims

1. Use of a composition comprising intact whey proteins for the preparation of a nutritional and/or a pharmaceutical composition for treating, preventing and/or improving metabolic dysfunctions and conditions associated with Type 2 diabetes mellitus.
2. The use according to claim 1, wherein the whey protein is sweet whey protein.
3. The use according to claim 1 or 2, wherein the amount of protein in the composition is in the range of from 1 to 90 % by weight, preferably from 5 to 70 % by weight, more preferably 11 to 50 % by weight, even more preferably 21 to 40 % by weight, most preferred about 25 to 35 % by weight, based on the total dry weight of the composition.
4. The use according to any preceding claim, for enhancing post-prandial insulinemia, stimulating insulin production, and/or decreasing blood glucose levels.
5. A method for treating, preventing and/or improving metabolic dysfunctions or conditions associated with Type 2 diabetes mellitus which comprises administering an effective amount of a composition containing intact whey proteins.
6. The method of claim 6 in which intact whey proteins are administered in an amount of 0.1 to 0.8g intact whey proteins per kg body weight.

use claim 1
101, 112 & 115
art

Sn. v such ✓

Wort ✓

f P ✓

BP1 can same reg.